Overview
This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy
Eligibility
Inclusion Criteria:
- Confirmed diagnosis of familial or acquired partial lipodystrophy
Exclusion Criteria:
- Treatment with any Investigational Medicinal Product (IMP) within 6 months or 5 times the terminal half-life of the corresponding IMP, whichever is longer, before the screening visit.
Other protocol defined inclusion/exclusion criteria apply
